Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High – Here’s What Happened

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $39.39 and last traded at $39.25, with a volume of 37092 shares traded. The stock had previously closed at $38.55.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SUPN. Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target for the company. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Performance

The company has a market cap of $2.16 billion, a P/E ratio of 36.59 and a beta of 0.90. The stock has a 50 day moving average price of $36.98 and a 200 day moving average price of $34.32.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same period in the previous year, the business earned ($0.29) earnings per share. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% compared to the same quarter last year. As a group, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Frank Mottola sold 15,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the transaction, the senior vice president now owns 8,200 shares in the company, valued at $303,236. This trade represents a 64.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 154,213 shares of company stock worth $5,660,180. Corporate insiders own 9.30% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Stephens Investment Management Group LLC boosted its position in shares of Supernus Pharmaceuticals by 1.8% in the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after buying an additional 33,710 shares during the period. Pacer Advisors Inc. lifted its stake in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares in the last quarter. Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the period. Victory Capital Management Inc. grew its stake in Supernus Pharmaceuticals by 1.1% during the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after acquiring an additional 7,833 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 14.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after purchasing an additional 91,354 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.